Ken Griffin Celldex Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$32.06 - $44.56 $2.3 Million - $3.19 Million	71,700 Added 587.7%	83,900 $2.85 Million
Q2 2024 Aug 14, 2024	SELL	$32.76 - $42.56 $537,264 - $697,984	-16,400 Reduced 57.34%	12,200 $451,000
Q1 2024 May 15, 2024	SELL	$35.22 - $51.88 $1.44 Million - $2.12 Million	-40,900 Reduced 58.85%	28,600 $1.2 Million
Q4 2023 Feb 14, 2024	SELL	$22.61 - $40.65 $85,918 - $154,470	-3,800 Reduced 5.18%	69,500 $2.76 Million
Q3 2023 Nov 14, 2023	BUY	$25.45 - $37.46 $1.38 Million - $2.04 Million	54,400 Added 287.83%	73,300 $2.02 Million
Q2 2023 Aug 14, 2023	SELL	$30.29 - $38.28 $81,783 - $103,356	-2,700 Reduced 12.5%	18,900 $641,000
Q1 2023 May 15, 2023	SELL	$34.78 - $47.43 $1.59 Million - $2.16 Million	-45,600 Reduced 67.86%	21,600 $777,000
Q4 2022 Feb 14, 2023	BUY	$27.78 - $45.38 $100,008 - $163,368	3,600 Added 5.66%	67,200 $3 Million
Q3 2022 Nov 14, 2022	SELL	$22.7 - $37.57 $9.13 Million - $15.1 Million	-402,400 Reduced 86.35%	63,600 $1.79 Million

207

67.3M

1.69M

980K

Ticker CLDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,772,400
Market Cap $1.25B
Description
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.